Figure 1From: Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasisDovitinib inhibited the growth and metastasis of HCC in an orthotopic xenograft model. A) Growth of MHCC-97H xenograft tumors was dose-dependently inhibited by dovitinib. The wet liver weight of 0, 25 and 50 mg/kg were 2.00 ± 0.54, 1.68 ± 0.31 and 1.41 ± 0.27 g, respectively. The four largest liver tumors of each group are shown. B) Significant inhibition of SMMC7721 xenograft tumors by dovitinib. The wet liver weight of 0, 25 and 50 mg/kg were 1.87 ± 0.45, 1.63 ± 0.26 and 1.56 ± 0.22 g, respectively. C) Dose-dependent inhibition of QGY-7703 xenograft tumors by dovitinib. The wet liver weight of 0, 25 and 50 mg/kg were 3.44 ± 0.72, 2.59 ± 0.45 and 1.91 ± 0.39 g, respectively. D) For the mice bearing the high-metastasis HCC cell line MHCC-97H, dose-dependent inhibition of lung metastases by dovitinib was observed under a microscope. The arrow points to macro-metastasis; scale bar, 100 μm. The results in panels A-C are expressed as the mean ± the standard deviation. black star, P < 0.05; double black star, P < 0.01.Back to article page